Comparative Pharmacology
Head-to-head clinical analysis: RENESE R versus TRIBENZOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENESE R versus TRIBENZOR.
RENESE-R vs TRIBENZOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic; inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and water reabsorption.
TRIBENZOR is a fixed-dose combination of olmesartan, an angiotensin II receptor blocker that inhibits the vasopressor and aldosterone-secreting effects of angiotensin II, and amlodipine, a dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in vasodilation.
Initial: 5 mg orally once daily, increased as needed to 10 mg once daily; maximum 10 mg/day.
Tribenzor (olmesartan medoxomil/amlodipine/hydrochlorothiazide) is available in fixed-dose combinations. Typical adult dose: one tablet orally once daily. Starting dose depends on prior antihypertensive therapy; maximum recommended dose is olmesartan 40 mg/amlodipine 10 mg/HCTZ 25 mg per day.
None Documented
None Documented
Terminal elimination half-life: 13-16 hours; clinical context: supports once-daily dosing
Terminal half-life 9-11 hours; supports once-daily dosing
Renal: 50% unchanged; fecal: 0%; biliary: 0%
Renal: 50-60% as unchanged drug and metabolites; Biliary/Fecal: 40-50%
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination